Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.
Becky JubbMarilyn LewisLynn McFadyenPaul SimpsonJulie MoriPhylinda ChanBarry WeatherleyElna van der RystMike WestbyCharles CraigPublished in: Antiviral chemistry & chemotherapy (2019)